Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 3/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16016403 | 0.84 | MPO (0.39) | MPOGPR84AKR1B1PCSK9SNCA | |
| SCHEMBL16020968 | 0.73 | MPO (0.39) | MPOAKR1B1PCSK9CD38P2RX7 | |
| SCHEMBL16016408 | 0.73 | MPO (0.42) | MPOGPR84AKR1B1PCSK9CD38 | |
| SCHEMBL15460004 | 0.70 | MPO (0.42) | MPOCD38P2RX7MAPTLMNA | |
| SCHEMBL16020970 | 0.70 | MPO (0.40) | MPOAKR1B1CD38P2RX7MAPT | |
| SCHEMBL22287928 | 0.69 | MPO (0.41) | MPOGPR84AKR1B1PCSK9 | |
| SCHEMBL13316625 | 0.69 | MPO (0.41) | MPOAKR1B1P2RX7MRGPRX4 | |
| SCHEMBL16016418 | 0.69 | MPO (0.41) | MPOAKR1B1CD38P2RX7MAPT | |
| SCHEMBL19335822 | 0.68 | TAAR1 (0.43) | MPOSLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL5412834 | 0.68 | GABRA1 (0.44) | MPOAKR1B1CD38P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200009-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | MPO 4689/4885GPR84 3291/4885AKR1B1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.